Francesco Passamonti

Summary

Affiliation: University of Pavia
Country: Italy

Publications

  1. ncbi request reprint Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
    Francesco Passamonti
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Am J Med 117:755-61. 2004
  2. ncbi request reprint Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders
    Francesco Passamonti
    Department of Hematology, IRCCS Policlinico San Matteo, 27100 Pavia, Italy
    Blood 107:3676-82. 2006
  3. ncbi request reprint Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients
    F Passamonti
    Institute of Hematology, University of Pavia, Policlinico San Matteo IRCCS, Viale Golgi 19, 27100 Pavia, Italy
    Haematologica 85:1011-8. 2000
  4. ncbi request reprint Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis
    Francesco Passamonti
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Br J Haematol 116:855-61. 2002
  5. ncbi request reprint Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation
    Francesco Passamonti
    Department of Hematology, University of Pavia Medical School, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico IRCCS Policlinico San Matteo, Pavia, Italy
    Blood 110:485-9. 2007
  6. doi request reprint A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
    Francesco Passamonti
    Department of Hematology Oncology, University of Pavia and Fondazione, Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, Pavia, Italy
    Blood 115:1703-8. 2010
  7. doi request reprint A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis
    Francesco Passamonti
    Department of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, University of Pavia, Italy
    Blood 111:3383-7. 2008
  8. ncbi request reprint Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman
    Francesco Passamonti
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Viale Golgi 19, Pavia, Italy
    Ann Hematol 83:495-7. 2004
  9. doi request reprint Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients
    Francesco Passamonti
    M D, Division of Hematology, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy
    Haematologica 93:1645-51. 2008
  10. ncbi request reprint Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman
    Francesco Passamonti
    Division of Hematology, University of Pavia, IRCCS Policlinico San Matteo, Viale Golgi 19, 27100, Pavia, Italy
    Leuk Lymphoma 44:1483-8. 2003

Detail Information

Publications65

  1. ncbi request reprint Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
    Francesco Passamonti
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Am J Med 117:755-61. 2004
    ..To assess life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia...
  2. ncbi request reprint Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders
    Francesco Passamonti
    Department of Hematology, IRCCS Policlinico San Matteo, 27100 Pavia, Italy
    Blood 107:3676-82. 2006
    ..This exemplifies a novel paradigm in which a somatic gain-of-function mutation is initially responsible for clonal expansion of hematopoietic cells and later for their abnormal trafficking via an activated cell progeny...
  3. ncbi request reprint Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients
    F Passamonti
    Institute of Hematology, University of Pavia, Policlinico San Matteo IRCCS, Viale Golgi 19, 27100 Pavia, Italy
    Haematologica 85:1011-8. 2000
    ..Polycythemia vera (PV) is a myeloproliferative disorder, characterized by the expansion of the red cell mass. Our purpose was to evaluate the efficacy of pipobroman (PB) in the long-term control of PV and to assess early and late events...
  4. ncbi request reprint Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis
    Francesco Passamonti
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Br J Haematol 116:855-61. 2002
    ..The low cumulative 10-year risk of thrombosis, leukaemia and solid tumours indicates that pipobroman is an adequate treatment for patients with high risk ET...
  5. ncbi request reprint Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation
    Francesco Passamonti
    Department of Hematology, University of Pavia Medical School, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico IRCCS Policlinico San Matteo, Pavia, Italy
    Blood 110:485-9. 2007
    ..A relationship was found between JAK2 (617V>F) and fetal loss (P = .05). This study indicates that patients carrying the JAK2 (617V>F) mutation have higher risk of developing pregnancy complications...
  6. doi request reprint A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
    Francesco Passamonti
    Department of Hematology Oncology, University of Pavia and Fondazione, Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, Pavia, Italy
    Blood 115:1703-8. 2010
    ..81 for intermediate-2 according to the age-adjusted DIPSS. The novelty of these models is the prognostic assessment of patients with PMF anytime during their clinical course, which may be useful for treatment decision-making...
  7. doi request reprint A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis
    Francesco Passamonti
    Department of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, University of Pavia, Italy
    Blood 111:3383-7. 2008
    ..In conclusion, leukocytosis at diagnosis of PV is a risk factor for evolution in post-PV MF. A dynamic score based on hemoglobin level, and platelet and leukocyte count predicts survival at any time from diagnosis of post-PV MF...
  8. ncbi request reprint Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman
    Francesco Passamonti
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Viale Golgi 19, Pavia, Italy
    Ann Hematol 83:495-7. 2004
  9. doi request reprint Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients
    Francesco Passamonti
    M D, Division of Hematology, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy
    Haematologica 93:1645-51. 2008
    ..Essential thrombocythemia is a chronic myeloproliferative disorder; patients with this disorder have a propensity to develop thrombosis, myelofibrosis, and leukemia...
  10. ncbi request reprint Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman
    Francesco Passamonti
    Division of Hematology, University of Pavia, IRCCS Policlinico San Matteo, Viale Golgi 19, 27100, Pavia, Italy
    Leuk Lymphoma 44:1483-8. 2003
    ..In conclusion, the use of PB is a definite alternative to hydroxyurea in patients with PV and ET at high risk of thrombosis...
  11. ncbi request reprint Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia
    Francesco Passamonti
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Italy
    Haematologica 88:13-8. 2003
    ..The aim of this study was to define the long-term risk of thrombosis, acute leukemia (AL) and myelofibrosis with myeloid metaplasia (MMM) in young PV patients...
  12. ncbi request reprint Leukemic transformation of polycythemia vera: a single center study of 23 patients
    Francesco Passamonti
    Division of Hematology, IRCCS San Matteo Polyclinic, University of Pavia, Pavia, Italy
    Cancer 104:1032-6. 2005
    ..Acute leukemia (AL) may occur as rare and late event of polycythemia vera (PV)...
  13. ncbi request reprint Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease
    Luca Arcaini
    Division of Haematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Br J Haematol 136:301-4. 2007
    ..In univariate analysis worse OS was associated with: FLIPI (P = 0.02), age > 60 years (P = 0.05) and raised lactate dehydrogenase (P = 0.05). In multivariate analysis, only FLIPI predicted a worse OS (P = 0.02)...
  14. ncbi request reprint Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations
    Emanuela Boveri
    Department of Surgical Pathology, University of Pavia Medical School, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    Br J Haematol 140:162-8. 2008
    ..003), and anaemia (P < 0.001) independently correlated with MVD. In summary, this study indicates that assessment of BM angiogenesis, as measured by MVD, may be a useful additional tool in the histopathological definition of CMD...
  15. pmc Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms
    Elisa Rumi
    Department of Molecular Medicine, University of Pavia, Pavia, Italy
    Blood 121:4388-95. 2013
    ..These observations suggest that acquired CN-LOH of chromosome 1p involving the MPL location may represent a molecular mechanism of fibrotic transformation in MPL-mutated myeloproliferative neoplasms...
  16. ncbi request reprint Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation
    Elisa Rumi
    Department of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Viale Golgi 49, 27100 Pavia, Italy
    J Clin Oncol 25:5630-5. 2007
    ..However, familial clustering is reported. The purpose of this study was to assess the prevalence and the clinical phenotype of familial CMDs, and to study the anticipation of disease onset in successive generations...
  17. pmc Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients
    Elisa Rumi
    Division of Hematology, Department of Hematology Oncology, University of Pavia Medical School and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    Haematologica 96:454-8. 2011
    ..No difference in familial clustering was observed between the two groups...
  18. ncbi request reprint Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination
    Luca Arcaini
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Viale Golgi 19, 27100 Pavia, Italy
    Oncologist 11:285-91. 2006
    ..This study describes the clinical features and the natural history of nongastric marginal-zone lymphomas and highlights that the dissemination to lymph nodes and bone marrow is associated with a poorer outcome...
  19. doi request reprint Blast phase of essential thrombocythemia: A single center study
    Francesco Passamonti
    Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Am J Hematol 84:641-4. 2009
    ..JAK2 (V617F)-positive ET may evolve in few instances into JAK2-negative leukemia. The outcome of patients is poor whatever the treatment used...
  20. ncbi request reprint Risk of second cancer in nongastric marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue: a population-based study from northern Italy
    Luca Arcaini
    Division of Hematology, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, University of Pavia, Pavia, Italy
    Clin Cancer Res 13:182-6. 2007
    ..The aim of this study was to define the risk of second cancer in nongastric marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT)...
  21. doi request reprint Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas
    Luca Arcaini
    Divison of Hematology, Fondazione IRCCS Policlinico S Matteo, University of Pavia, Viale Golgi 19, Pavia, Italy
    Am J Hematol 85:46-50. 2010
    ..This could be a limit to the application of immunochemotherapy programs. HCV+ lymphomas represent a distinct clinical subset of NHL that deserves specific clinical approach to limit liver toxicity and ameliorate survival...
  22. ncbi request reprint Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders
    Francesco Passamonti
    Division of Hematology, University of Pavia Medical School and IRCCS Policlinico S Matteo, Pavia, Italy
    Haematologica 88:1123-9. 2003
    ....
  23. ncbi request reprint JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders
    Elisa Rumi
    Department of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo and University of Pavia School of Medicine, Pavia, Italy
    Cancer 107:2206-11. 2006
    ..The authors studied the biologic significance of the JAK2 (V617F) mutation in familial myeloproliferative disorders...
  24. ncbi request reprint Role of the molecular staging and response in the management of follicular lymphoma patients
    Luca Arcaini
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Italy
    Leuk Lymphoma 47:1018-22. 2006
    ..Absence of the bcl-2 rearrangement is related to a better EFS and the achievement of a molecular response in peripheral blood after therapy is associated with a better EFS...
  25. doi request reprint Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes
    Matteo Giovanni Della Porta
    Department of Hematology, University of Pavia Medical School, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    J Clin Oncol 27:754-62. 2009
    ..We studied bone marrow (BM) histologic abnormalities in myelodysplastic syndromes (MDS) classified according to WHO criteria to determine their clinical correlates and prognostic value...
  26. doi request reprint Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm
    Elisa Rumi
    Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Am J Hematol 86:974-9. 2011
    ....
  27. ncbi request reprint Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts
    Francesco Passamonti
    Division of Hematology, Department of Medicine, University Hospital Ospedale di Circolo e Fondazione Macchi, Varese, Italy
    Blood 123:1833-5. 2014
    ..9-7.8 vs 3.5 years, 95% CI: 3.0-3.9) with a hazard ratio of 0.61 (95% CI: 0.41-0.91; P = .0148). This observation suggests that ruxolitinib may modify the natural history of PMF. ..
  28. pmc Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS
    Chiara Elena
    Department of Hematology Oncology, Division of Hematology, University of Pavia Medical School and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    Haematologica 96:167-70. 2011
    ..This study suggests that red blood cell transfusion-dependency should be considered to improve risk stratification of primary myelofibrosis during follow up...
  29. doi request reprint Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia
    Alessandra Carobbio
    Division of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Am J Hematol 87:203-4. 2012
    ....
  30. doi request reprint Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis
    Luca Malcovati
    Department of Hematology Oncology, University of Pavia and Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico IRCCS, Policlinico San Matteo, Pavia, Italy
    Blood 114:3538-45. 2009
    ....
  31. ncbi request reprint Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up
    Ercole Brusamolino
    Clinica Ematologica and Servizio di Radioterapia Oncologica, Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, University of Pavia, Pavia, Italy
    Clin Cancer Res 12:6487-93. 2006
    ..To report on long-term events after short doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy and adjuvant radiotherapy in favorable early-stage Hodgkin's lymphoma...
  32. doi request reprint Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry
    Michele Merli
    Department of Oncohematology, Fondazione IRCCS Policlinico S Matteo, University of Pavia, Italy
    Eur J Haematol 85:405-15. 2010
    ..In FL, diffuse large B-cell lymphoma (DLBCL) and LPL, FC underestimates the extent of infiltrate with respect to histology...
  33. ncbi request reprint Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma
    Mario Lazzarino
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Oncology 68:146-53. 2005
    ..Because of the different mechanisms of action and non-overlapping toxicities, combination of rituximab with chemotherapy is a rational approach...
  34. ncbi request reprint High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma
    Francesca Novara
    Department of Human end Hereditary Pathology, Section of Medical Genetics, University of Pavia, Pavia 27100, Italy
    Hum Pathol 40:1628-37. 2009
    ..01) and del(17p) (P = .02). Hepatitis C virus-positive splenic marginal zone B-cell lymphoma patients have no specific chromosome alterations. Patients with poor prognosis are characterized by distinctive imbalances...
  35. ncbi request reprint Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders
    Francesco Passamonti
    Division of Haematology, University of Pavia Medical School and IRCCS Policlinico S Matteo, 27100 Pavia, Italy
    Br J Haematol 126:650-6. 2004
    ..From a clinical viewpoint, neutrophil CD177 mRNA overexpression is rather a marker of abnormal neutrophil production and/or release in patients with CMD...
  36. ncbi request reprint Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment
    Luca Arcaini
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Viale Golgi 19, 27100 Pavia, Italy
    Leuk Res 30:277-82. 2006
    ..Aim of this study was to validate the FLIPI score in an independent series of follicular lymphoma patients and to correlate prognostic categories with the period of diagnosis and the use of anthracycline...
  37. doi request reprint Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations
    Francesco Passamonti
    Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Blood 117:2813-6. 2011
    ..These findings suggest that, despite the phenotypical difference, the outcome of JAK2 exon 12 mutations-positive PV is similar to that of JAK2 (V617F)-positive PV...
  38. pmc Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
    Giovanni Barosi
    Center for the Study of Myelofibrosis, Biotechnology Research Area, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S Matteo Foundation, Pavia, Italy
    Blood 121:4778-81. 2013
    ..We anticipate that these criteria will be adopted widely to facilitate the development of new and more effective therapies for ET and PV...
  39. doi request reprint Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires
    Luca Arcaini
    Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia Viale C Golgi 19, 27100 Pavia, Italy
    Blood Cells Mol Dis 42:286-91. 2009
    ....
  40. ncbi request reprint Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia
    Elisa Rumi
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Am J Hematol 81:124-7. 2006
    ..This case points to the importance of suspecting pulmonary EMH when unexplained progressive dyspnea occurs in a patient with MMM. Early recognition of pulmonary EMH may prevent PH and favor a better response to therapy...
  41. ncbi request reprint Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma
    Luca Arcaini
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Italy
    Clin Lymphoma 4:250-2. 2004
    ..The immunochemotherapy regimen was well tolerated and all patients exhibited complete remission. To our knowledge, this is the first report of splenic MZL showing response to a combination of rituximab with chemotherapy...
  42. ncbi request reprint Mutational status of myeloproliferative neoplasms
    Elisa Rumi
    Department of Oncology and Hematology, Division of Hematology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy 27100
    Crit Rev Eukaryot Gene Expr 20:61-76. 2010
    ..Implications of these mutations in the understanding of the pathogenesis of myeloproliferative neoplasms and in the clinical phenotype are discussed in this review...
  43. pmc Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms
    Daniela Pietra
    Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
    Haematologica 96:607-11. 2011
    ..In 3 cases carrying double MPL mutations, deep sequencing analysis showed identical load and location in cis of the paired lesions, indicating their simultaneous occurrence on the same chromosome...
  44. ncbi request reprint Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making
    Luca Malcovati
    Division of Hematology, IRCCS, Policlinico San Matteo, 27100 Pavia, Italy
    J Clin Oncol 23:7594-603. 2005
    ....
  45. pmc Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies
    Francesco Passamonti
    Division of Hematology, Department of Internal Medicine, Ospedale di Circolo e Fondazione Macchi, Varese, Italy
    Oncotarget 2:485-90. 2011
    ..On the other hand, JAK inhibitors have not thus far shown disease-modifying activity therefore any other deduction on these new drugs seems premature...
  46. doi request reprint New generation small-molecule inhibitors in myeloproliferative neoplasms
    Francesco Passamonti
    Division of Hematology, Department of Internal Medicine, Ospedale di Circolo e Fondazione Macchi, Varese, Italy
    Curr Opin Hematol 19:117-23. 2012
    ..Myeloproliferative neoplasms (MPNs) are diseases that carry the JAK2 (V617F) mutation in about 70% of the patients. The purpose of this review is to describe the recent advances in the therapy of MPNs with JAK2 inhibitors...
  47. doi request reprint A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment
    Francesco Passamonti
    Division of Hematology, Department of Internal Medicine, University Hospital Ospedale di Circolo e Fondazione Macchi, Varese, Italy
    Blood 120:1197-201. 2012
    ....
  48. doi request reprint Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet
    Tiziano Barbui
    Unit of Clinical Epidemiology Center for the Study of Myelofibrosis, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S Matteo, Viale Golgi 19, 27100 Pavia, Italy
    J Clin Oncol 29:761-70. 2011
    ..The risk of allogeneic stem-cell transplantation-related complications is justified in transplantation-eligible patients whose median survival time is expected to be less than 5 years...
  49. pmc Novel agents in indolent lymphomas
    Michele Merli
    Division of Hematology, Department of Internal Medicine, Ospedale di Circolo and Fondazione Macchi, University of Insubria, Varese, Italy
    Ther Adv Hematol 4:133-48. 2013
    ..The development of these new drugs may change in the near future the approach to iNHL patients, leading to better tolerated and effective therapy regimens...
  50. doi request reprint Clinical predictors of outcome in MPN
    Francesco Passamonti
    Division of Hematology, Department of Internal Medicine, Ospedale di Circolo e Fondazione Macchi, Viale Borri 57, 21100 Varese, Italy
    Hematol Oncol Clin North Am 26:1101-16. 2012
    ..Patients with PMF may encounter many complications associated with disease progression or with PMF evolution. This article defines factors that determine prognosis in these 3 diseases...
  51. ncbi request reprint Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders
    Daniela Pietra
    Department of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy
    Blood 111:1686-9. 2008
    ..Moreover, a genetic predisposition to acquisition of different JAK2 mutations is inherited in families with myeloproliferative disorders...
  52. doi request reprint Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis
    Francesco Passamonti
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Clin Lymphoma Myeloma Leuk 11:S25-7. 2011
    ..This model may also predict survival when applied during follow-up...
  53. pmc High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis
    Vittorio Rosti
    Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, IRCCS Policlinico S Matteo Foundation, Pavia, Italy
    PLoS ONE 5:e15277. 2010
    ..Due to inherent performance limitations of ECFCs assay, there is an urgent need to arrive to an acceptable standardization of ECFC assessment...
  54. ncbi request reprint Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles
    Luca Arcaini
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Italy
    Cancer 100:107-15. 2004
    ..Splenic and nodal marginal zone lymphomas (MZL) are subtypes of marginal zone-derived neoplasms. Due to their rarity, little is known concerning their relation, pattern of dissemination, and treatment outcome...
  55. doi request reprint New and old prognostic factors in polycythemia vera
    Francesco Passamonti
    Division of Hematology, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Viale Golgi 19, 27100, Pavia, Italy
    Curr Hematol Malig Rep 4:19-24. 2009
    ..The role of the JAK2V617F mutation as a prognostic factor requires further validation, but it may have a dominant role in disease progression and in the activation of platelets and leukocytes...
  56. doi request reprint How I treat polycythemia vera
    Francesco Passamonti
    Division of Hematology, Department of Internal Medicine, University Hospital Ospedale di Circolo e Fondazione Macchi, Viale L Borri 57, Varese, Italy
    Blood 120:275-84. 2012
    ..In this paper, I discuss the main problems encountered in daily clinical practice with PV patients regarding diagnosis, prognostication, and therapy...
  57. pmc Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma
    Silvia Zibellini
    Division of Hematology, Department of Oncohematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Viale Golgi 19, Pavia, Italy
    Haematologica 95:1792-6. 2010
    ..Overall, data suggest that the pathogenesis of splenic marginal zone lymphoma may involve also HCV-unrelated epitopes or an antigenic trigger common to other indolent lymphomas...
  58. doi request reprint Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference
    Giovanni Barosi
    Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S Matteo, Pavia, Italy
    Blood 113:4829-33. 2009
    ..The combined use of these response definitions should help standardize the design and reporting of clinical studies...
  59. ncbi request reprint Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases
    Valeria Brazzelli
    Department of Human and Hereditary Pathology, Institute of Dermatology, Pavia, Italy
    J Am Acad Dermatol 53:S240-3. 2005
    ..To our knowledge this is the first reported PR-like cutaneous eruption to IM...
  60. ncbi request reprint A gain-of-function mutation of JAK2 in myeloproliferative disorders
    Robert Kralovics
    Department of Research, Experimental Hematology, University Hospital Basel, Basel, Switzerland
    N Engl J Med 352:1779-90. 2005
    ..The loss of heterozygosity (LOH) on the short arm of chromosome 9 (9pLOH) in myeloproliferative disorders suggests that 9p harbors a mutation that contributes to the cause of clonal expansion of hematopoietic cells in these diseases...
  61. ncbi request reprint Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug
    Francesco Passamonti
    Haematologica 89:1284. 2004
  62. ncbi request reprint Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders
    Mario Cazzola
    Haematologica 91:159. 2006
  63. ncbi request reprint Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
    Robert Kralovics
    Experimental Hematology, Department of Research, Division of Clinical Hematology, Division of Pneumology, Basel University Hospital, Switzerland
    Blood 106:3374-6. 2005
    ....
  64. ncbi request reprint JAK2 (V617F) mutation in healthy individuals
    Francesco Passamonti
    Br J Haematol 136:678-9. 2007
  65. doi request reprint Disease anticipation in familial myeloproliferative neoplasms
    Elisa Rumi
    Blood 112:2587-8; author reply 2588-9. 2008